News

Proteomics International (ASX:PIQ) secures licence for oesophageal cancer biomarkers – The Market Herald

Under the contract, QIMR’s intellectual property in the biomarkers will become licensed exclusively to Proteomics, which the company will use to develop and commercialise a simple blood test for the cancer

Proteomics says it will now undertake additional studies to confirm the diagnostic performance of the potential new blood test, which will take approximately six months

Article: Proteomics International (ASX:PIQ) secures licence for oesophageal cancer biomarkers

Subscribe
  • This field is for validation purposes and should be left unchanged.